1,3,3-Trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine]

Catalog No. :
ACNKOA635
CAS No. :
114747-45-4
Molecular Formula :
C27H29N3O
Molecular Weight :
411.55

IUPAC Name:1,3,3-trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine]

1,3,3-Trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine] structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
5g97%$81.00Login to see priceIn stockInquiry
10g97%$138.00Login to see priceInquiryInquiry
25g97%$262.00Login to see priceIn stockInquiry
100g97%$961.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,3,3-Trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine]
IUPAC Name1,3,3-trimethyl-6'-(piperidin-1-yl)spiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine]
MDL No.MFCD00329486
Molecular FormulaC27H29N3O
Molecular Weight411.55
SMILESCC1(C)C2(OC3=CC(N4CCCCC4)=C5C=CC=CC5=C3N=C2)N(C)C6=C1C=CC=C6
InChI KeyYAWJWXXKKHOMQT-UHFFFAOYSA-N
SynonymTechnocolor Purple 3
CAS No.114747-45-4
PubChem CID5125966

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACNKOA635 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNKOA635 route product structure diagram
    ACNKOA635114747-45-4 In Stock
Inquiry

2. ACNKOA635 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACNKOA635 route product structure diagram
    ACNKOA635114747-45-4 In Stock
Inquiry

Comments (0)